Goat Anti-ACPP / PAP Antibody

$464.00

SKU Unit Size Price

Select a unit size:


SKU: EB09390
Formulation
Supplied at 0.5 mg/ml in Tris saline, 0.02% sodium azide, pH7.3 with 0.5% bovine serum albumin.
Unit Size
100 µg
Storage Instructions
Aliquot and store at -20°C. Minimize freezing and thawing.
Synonym / Alias Names
prostatic acid phosphotase|PAP|ACP3|ACP-3|acid phosphatase, prostate|ACPP
Usage Summary
Immunofluorescence:: This antibody has been successfully used in IF on Mouse: Nousiainen HO et al. (2014) PMID: 24846136.
Accession ID
NP_001090.2
Blocking Peptide
EBP09390
Immunogen
Peptide with sequence C-YGIHKQKEKSRLQ, from the internal region of the protein sequence according to NP_001090.2.
Product Comments
This antibody is expected to recognize both isoforms (NP_001090.2; NP_001127666.1).
Peptide Sequence
C-YGIHKQKEKSRLQ
Purification Method
Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide.
Shipping Instructions
Refrigerated
Predicted Species
Human, Mouse, Rat, Dog, Cow
Reactive Species
Human, Mouse
Human Gene ID
55
Mouse Gene ID
56318
Rat Gene ID
56780
Product Grade
IHC Results
In paraffin embedded Human Prostate shows cytoplasm staining in some secretory cells of the gland. Recommended concentration, 3-5µg/ml. This antibody has been successfully used in IHC on Mouse: Nousiainen HO et al. (2014) PMID: 24846136.
ELISA Detection Limit
Antibody detection limit dilution 1:64000.
Western Blot
Approx 50kDa band observed in Human Prostate lysates (calculated MW of 44.6kDa according to NP_001090.2). The observed molecular weight corresponds to earlier findings in literature with different antibodies (Patel et al, ,Clin Chem. 1986 Oct;32(10):1832-5. PMID: 3530530). Recommended concentration: 0.3-1µg/ml.
Application Type
Pep-ELISA, WB, IHC, IF
Selected References
[{"pmid": 24846136, "intro": "This antibody has been successfully used in IHC and IF on Mouse:", "title": "Mice deficient in transmembrane prostatic Acid phosphatase display increased GABAergic transmission and neurological\r\nalterations.", "author": "Nousiainen HO, Quintero IB, Myöhänen TT, Voikar V, Mijatovic J, Segerstråle M, Herrala AM, Kulesskaya N, Pulkka AE, Kivinummi T, Abo Ramadan U, Taira T, Piepponen TP, Rauvala H, Vihko P.", "journal": "PLoS One. 2014 May 20;9(5):e97851."}]